190 related articles for article (PubMed ID: 36927689)
1. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Hou X; Du H; Deng Y; Wang H; Liu J; Qiao J; Liu W; Shu X; Sun B; Liu Y
J Transl Med; 2023 Mar; 21(1):198. PubMed ID: 36927689
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Li XC; Wu BS; Jiang Y; Li J; Wang ZF; Ma C; Li YR; Yao J; Jin XQ; Li ZQ
Drug Des Devel Ther; 2021; 15():1641-1652. PubMed ID: 33907383
[TBL] [Abstract][Full Text] [Related]
3. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
4. Glioma and temozolomide induced alterations in gut microbiome.
Patrizz A; Dono A; Zorofchian S; Hines G; Takayasu T; Husein N; Otani Y; Arevalo O; Choi HA; Savarraj J; Tandon N; Ganesh BP; Kaur B; McCullough LD; Ballester LY; Esquenazi Y
Sci Rep; 2020 Dec; 10(1):21002. PubMed ID: 33273497
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
6. Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Li M; Ren T; Lin M; Wang Z; Zhang J
J Proteomics; 2020 Jan; 211():103578. PubMed ID: 31689562
[TBL] [Abstract][Full Text] [Related]
7. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
9. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
10. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
11. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
[TBL] [Abstract][Full Text] [Related]
12. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
13. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755
[TBL] [Abstract][Full Text] [Related]
14. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Hua L; Huang L; Zhang X; Feng H
J Biosci; 2020; 45():. PubMed ID: 32975228
[TBL] [Abstract][Full Text] [Related]
18. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Wei Y; Duan S; Gong F; Li Q
Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
[TBL] [Abstract][Full Text] [Related]
19. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
20. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
